REG - Convatec Group PLC - CEO and CFO appointments

ConvaTecAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251106:nRSF3877Ga&default-theme=true

RNS Number : 3877G  Convatec Group PLC  06 November 2025

 

 

Chief Executive Officer and Chief Financial Officer appointments

 

 

London, UK, 6 November 2025 - The Board of Directors of Convatec is pleased to
announce the appointments of Jonny Mason as Chief Executive Officer and Fiona
Ryder as Chief Financial Officer, with immediate effect.

 

Dr John McAdam, Chair of the Board of Directors, said:

"Since joining the business in 2022 as CFO, Jonny has demonstrated exceptional
leadership and is highly regarded for his contribution to Convatec's
successful turnaround. Jonny has extensive experience leading publicly listed
and international businesses. The Board is confident in his ability to build
on the successful transformation led by Karim over the last 6 years, and
enable Convatec to deliver its full potential.

 

Fiona's appointment demonstrates the strength of internal talent that Convatec
has built. She is a seasoned finance leader with a strong track record in
global businesses, having led finance functions while based in the UK, US and
Singapore. She has played a pivotal role in delivering Convatec's focus on
simplification and productivity, has been fundamental to the success of the
FISBE strategy.

 

I look forward to working with Jonny and Fiona to deliver value for all our
stakeholders, making a real difference to the lives of people relying on
Convatec's products, services and solutions."

 

Jonny Mason, Chief Executive Officer, said:

"Convatec is a brilliant business, full of talented colleagues, making a real
difference to the lives of millions of people around the world. As we
accelerate our growth and scale up the richest innovation pipeline in
Convatec's history, we have significant potential ahead of us. Above all else,
we will remain focused on delivering our vision, pioneering trusted medical
solutions to improve the lives we touch. As my close colleague and friend
Karim often said, Convatec's best days are ahead of us, and I'm determined to
prove that he was right."

 

Fiona Ryder, Chief Financial Officer, said:

"I am very pleased for the opportunity to continue to build on what we have
achieved through Convatec's turnaround and to support our teams to realise
Convatec's full potential. The opportunities ahead of us are substantial. I'm
looking forward to continuing to work with Jonny and the team to deliver our
plans for the benefit of all our stakeholders."

 

Jonny Mason joined Convatec on 31 January 2022 as Chief Financial Officer and
became a Director of the Company from 12 March 2022. He was appointed Interim
CEO on 4 August 2025. Fiona Ryder joined Convatec on 3 January 2022 as Group
Financial Controller and became Interim CFO on 4 August 2025. Fiona will
become a Director of the Company from 6 November 2025.

 

Notes

There is no other information to be disclosed under UK Listing Rule 6.4.8 R in
relation to the appointment of Fiona Ryder.

 

Jonny Mason and Fiona Ryder will be paid in accordance with the Company's
Directors' Remuneration Policy. Full details of Jonny Mason's and Fiona
Ryder's remuneration arrangements will be disclosed in the Directors'
Remuneration Report for 2025.

 

Contacts

Media: mediarelations@convatec.com (mailto:mediarelations@convatec.com)

Analysts & investors: ir@convatec.com (mailto:ir@convatec.com)

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a global medical products and technologies company, focused on solutions
for the management of chronic conditions, with leading positions in Advanced
Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than
10,000 colleagues, we provide products and services in around 90 countries,
united by a promise to be forever caring. Our solutions provide a range of
benefits, from infection prevention, treatment for hard to heal wounds,
at-risk skin and ulcerated tissue to supporting debilitating conditions,
improved patient outcomes and reduced care costs. Convatec's revenues in 2024
were over $2 billion. The company is a constituent of the FTSE 100 Index
(LSE:CTEC). To learn more please visit http://www.convatecgroup.com
(https://www.convatecgroup.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPKPBNFBDDBDK



            Copyright 2019 Regulatory News Service, all rights reserved